| << Back |
| Portola Pharmaceuticals Announces Executive Leadership Change |
The Company has engaged a leading executive search firm to assist management in identifying and recruiting a new chief commercial officer in parallel with the Company’s search for a chief executive officer. During the transition period, “On behalf of the entire management team, I’d like to thank Tao for his many contributions during a critical period in Portola’s evolution,” said Ms. Dier. “Tao led two nearly simultaneous U.S. product launches and played an integral role in our transition from an R&D organization into a commercial company. We are grateful for his many contributions and wish him all the best in future endeavors.” Ms. Dier added: “During this transitional period, our top priority remains the Andexxa Early Supply Program, which we launched in May and is continuing to gain momentum, and we are implementing a focused commercial strategy for Bevyxxa. Additionally, we are looking forward to a number of significant regulatory milestones that will drive the Company’s long-term growth, including the potential U.S. regulatory approval of the large-scale Generation 2 Andexxa manufacturing process, European approval of andexanet alfa, and the potential regulatory path forward for cerdulatinib, our Syk/JAK inhibitor and the third novel compound discovered in our labs.” About Investor Contact: Media Contact:
|
 Print Page |  E-mail Page |  RSS Feeds |  E-mail Alerts |
